Formulation and evaluation of transdermal patch of Aceclofenac by Patel, Rakesh P. et al.
International Journal of Drug Delivery 1(2009) 41-51 
http://www.arjournals.org/ijodd.html 
 
Research article 
                                                            
ISSN: 0975-0215 
Formulation and evaluation of transdermal patch of Aceclofenac 
 
Rakesh P. Patel1*, Grishma Patel1, Ashok Baria1
 
*Corresponding author: 
Rakesh P. Patel 
 
1S. K. Patel College of 
Pharmaceutical Education and   
Research,  Ganpat University, 
Ganpat vidyanagar, Kherva, 
Mehsana-Gozaria Highway, , 
Gujarat, India. PIN-390 001 
 
raka_77us@yahoo.com 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract: 
The purpose of this research was to develop a matrix-type transdermal 
therapeutic system containing drug Aceclofenac with different ratios of 
hydrophilic (hydroxyl propyl cellulose) and hydrophobic (ethyl cellulose) 
polymeric systems by the solvent evaporation technique by using 15 % w/w 
of dibutyl phthalate to the polymer weight, incorporated as plasticizer. 
Different concentrations of oleic acid and isopropyl myristate were used to 
enhance the transdermal permeation of Aceclofenac. The physicochemical 
compatibility of the drug and the polymers studied by differential scanning 
calorimetry and infrared spectroscopy suggested absence of any 
incompatibility. Formulated transdermal films were physically evaluated with 
regard to thickness, weight variation, drug content, flatness, tensile strength, 
folding endurance, percentage of moisture content and water vapour 
transmission rate. All prepared formulations indicated good physical stability. 
In-vitro permeation studies of formulations were performed by using Franz 
diffusion cells.  Formulation prepared with hydrophilic polymer containing 
permeation enhancer showed best in-vitro skin permeation through rat skin 
(Wistar albino rat) as compared to all other formulations. The results 
followed the release profile of Aceclofenac followed mixed zero-order and 
first-order kinetics in different formulation. However, the release profile of 
the optimized formulation F9 (r2 = 0.9935 for Higuchi) indicated that the 
permeation of the drug from the patches was governed by a diffusion 
mechanism. Formulation F9 showed highest flux among all the formulations 
and 1.369 fold enhancements in drug permeation. These results indicate that 
the formulation containing 15 % of oleic acid with 10 % Isopropyl myristate 
give better penetration of Aceclofenac through rat skin.   
 
 
Keywords:  Aceclofenac, Transdermal Film, Permeation enhancer, In-vitro 
permeation study. 
 
Introduction 
Transdermal drug administration generally refers to 
topical application of agents to healthy intact skin 
either for localized treatment of tissues underlying the 
skin or for systemic therapy. For transdermal products  
 
the goal of dosage design is to maximize the flux 
through the skin into the systemic circulation and 
simultaneously minimize the retention and 
metabolism of the drug in the skin [1]. Transdermal 
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drug delivery has many advantages over the oral route 
of administration such as improving patient 
compliance in long term therapy, bypassing first-pass 
metabolism, sustaining drug delivery, maintaining a 
constant and prolonged drug level in plasma, 
minimizing inter- and intra patient variability, and 
making it possible to interrupt or terminate treatment 
when necessary [2,3]  
The mode of action of Aceclofenac (ACF) is largely 
based on the inhibition of prostaglandin synthesis. 
ACF is a potent inhibitor of the enzyme 
cyclooxygenase (Cox), which is involved in the 
production of prostaglandins. In-vitro data indicate 
inhibition of Cox-1 and Cox-2 by ACF in whole 
blood assays, with selectivity for Cox-2 being evident 
[4]. ACF has shown stimulatory effects on cartilage 
matrix synthesis that may be linked to the ability of 
the drug to inhibit IL-1 activity. In-vitro data indicate 
stimulation by the drug of synthesis of 
glycosaminoglycan in osteoarthritic cartilage.  The 
duration of morning stiffness and pain intensity are 
reduced and spinal mobility improved, by ACF in 
patients with ankylosing spondylitis [5] (Laurent et 
al., 2000). ACF is metabolized to a major metabolite, 
4'-hydroxy ACF and to a number of other metabolites 
including 5-hydroxy ACF, 4'-hydroxydiclofenac, 
diclofenac and 5-hydroxydiclofenac [6]  
There are reports describing the use of hydroxyl 
propyl cellulose (HPC) in transdermal patches and 
ophthalmic preparations [7-9] and ethyl cellulose 
(EC) transdermal delivery systems as well as other 
dosage forms for controlled release of drugs [10-12] 
HPC is freely water soluble, whereas EC is 
hydrophobic. So the transdermal delivery systems 
were prepared using HPC and EC to study the effect 
of hydrophilic and hydrophobic nature of polymer on 
release of ACF. A large number of fatty acids and 
their esters have been used as permeation enhancers. 
Oleic acid has been shown to be effective as a 
permeation enhancer for many drugs, for example 
increasing the flux of salicylic acid 28-fold and 5-
fluorouracil flux 56-fold, through human skin 
membranes in-vitro [13,14]. It has also been used for 
ketoprofen [15], flurbiprofen [16], 5-FU, estradiol  
[14], zalcitabine, didanosine, zidovudine [17], etc. 
 
The aims of the present study were to (1) prepare 
transdermal patches of ACF  using hydrophilic and 
hydrophobic polymer; (2) optimization of transdermal 
patch formulation using 32 full factorial design; and 
(3) study the in-vitro diffusion behavior of prepared 
transdermal patch formulations in the presence and 
absence of penetration enhancer. The purpose was to 
provide the delivery of the drug at a controlled rate 
across intact skin. 
 
Materials and Methods 
                                                                          
ACF was received as a gift samples from Lincoln 
Pharmaceticals, Ahmedabad, India. Hydroxyl propyl 
cellulose (HPC) and ethyl cellulose (EC) were 
generous gift from Colorcon Asia Pvt. Ltd (Mumbai, 
India) and Maan Pharmaceuticals Ltd. (Ahmedabad, 
India), respectively. Oleic acid (OA) and di-n-butyl-
phthalate (DBP) were procured from Sigma 
Chemicals Ltd. (Ahmedabad, India). Other materials 
used in the study (chloroform, methanol, 
dichloromethane, glycerol, potassium dihydrogen 
phosphate, etc.) were of analytical grade. Double-
distilled water was used throughout the study. 
 
 
Investigation of Physicochemical Compatibility of 
Drug and Polymer 
 
The physicochemical compatibility between ACF and 
polymers used in the films was studied by using 
differential scanning calorimetry (DSC- Shimadzu 60 
with TDA trend line software, Shimadzu Co., Kyoto, 
Japan) and fourier transform infrared (FTIR- 8300, 
Shimadzu Co., Kyoto, Japan) spectroscopy.  
 
In DSC analysis, the samples were weighed (5 mg), 
hermetically sealed in flat bottom aluminum pans, 
and heated over a temperature range of 50 to 300°C at 
a constant increasing rate of 10°C/min in an 
atmosphere of nitrogen (50 mL/min). The 
thermograms obtained for ACF, polymers, and 
physical mixtures of ACF with polymers were 
compared. The infrared (IR) spectra were recorded 
using an FTIR by the KBr pellet method and spectra 
were recorded in the wavelength region between 4000 
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and 400 cm–1. The spectra obtained for ACF, 
polymers, and physical mixtures of ACF with 
polymers were compared. 
Preparation of Transdermal Films 
Transdermal patches containing ACF were 
prepared by the solvent evaporation technique in 
cylindrical glass molds with both sides opens [18]. 
The backing membrane was cast by pouring a 2 % 
(m/V) polyvinyl alcohol (PVA) solution followed by 
drying at 60 °C for 6 h. The drug reservoir was 
prepared by dissolving HPC or EC in Chloroform: 
Methanol (1:1) mixture. Dibutyl phthalate 15 % (w/w 
of dry polymer composition) was used as a 
plasticizer. The drug 50 mg (in 5 mL solvent mixture 
Chloroform: Methanol) was added into the 
homogeneous dispersion under slow stirring with a 
magnetic stirrer. The uniform dispersion was cast on a 
PVA backing membrane and dried at room 
temperature. (Table 1) The films were stored between 
sheets of wax paper in a desiccator. 
 
Table 1: Composition of transdermal patches 
 
Formulation code 
 
Sr. 
No. 
Ingredients 
A1 A2 A3 A4 A5 A6 
1 Drug (mg) 50 50 50 50 50 50 
2 HPC 150 200 250 - - - 
3 EC - - - 150 200 250 
4 Dibutyl phthalate* 
(ml)  
0.02
15 
0.02
87 
0.03
58 
0.02
15 
0.02
87 
0.03
58 
5 Methanol (ml) 2.5 2.5 2.5 2.5 2.5 2.5 
6 Chloroform (ml) 2.5 2.5 2.5 2.5 2.5 2.5 
 
Note: * 15 % w/w of dibutyl phthalate to the polymer weight, 
incorporated as plasticizer. The above formula gave patch of 19.63 sq. 
cm. area 
 
 
Physicochemical characterization of films 
 
Thickness 
The thickness of patches was measured at three 
different places using a micrometer (Mitutoyo Co., 
Japan) and mean values were calculated [19]. 
 
Weight Variation 
The patches were subjected to mass variation by 
individually weighing randomly selected patches. 
Such determinations were carried out for each 
formulation [20]. 
 
Table 2: Evaluation of transdermal patches 
 
Parameters A1 A2 A3 A4 A5 A6 
Thickness (μm) 120 ± 3.6 135 ± 4.05 142 ± 
4.26 
186 ± 5.58 206 ± 
6.18 
215 ± 
6.45 
Weight variation  
(mg cm-2) 
10.61 ± 
0.31 
12.51± 
0.37 
14.97 ± 
0.44 
10.11 ± 
0.30 
12.74 ± 
0.38 
15.13 ± 
0.45 
Drug content (%) 98.3 ±  
2.94 
99.0 ± 
2.97 
98.2 ± 
2.94 
99.2 ± 
2.97 
98.7 ± 
2.96 
97.9 ± 
2.93 
Folding endurance 209 ± 6.27 213 ± 6.39 210 ± 
6.3 
234 ± 7.02 245 ± 
7.35 
238 ± 
7.14 
Tensile strength 
(kg cm-2) 
3.15 ± 
0.094 
3.51 ± 
0.105 
3.83 ± 
0.114 
2.12 ± 
0.063 
2.25 ± 
0.067 
2.98 ± 
0.089 
Moisture content 
(%) 
2.32 ± 
0.56 
2.92 ± 
0.68 
4.02 ± 
0.89 
1.96 ± 
0.39 
1.78 ± 
0.33 
1.64 ± 
0.31 
WVTR (mg cm–2 
h–1) 
0.468 ± 
0.014 
0.482 ± 
0.014 
0.569 ± 
0.017 
0.121 ± 
0.003 
0.268 ± 
0.008 
0.140 ± 
0.004 
mean ± SD (n=3) 
 
 
Table 3: Properties of Transdermal patches containing ACF 
 
F. 
Code 
Thickness 
(μm) 
Weight 
variation 
(mg) 
Drug 
content 
(%) 
Folding 
endurance 
Tensile 
strength 
(kgcm-2) 
F1 160 ± 5.60 10.6 ± 10.37 97.9 ± 2.42 198 ± 6.93 2.65 ± 0.092 
F2 168 ± 5.88 11.12 ± 0.38 98.6 ± 2.45 202 ± 7.07 2.98 ± 0.104 
F3 170 ± 5.95 10.23 ± 0.35 97.5 ± 2.41 215 ± 7.52 3.10 ± 0.108 
F4 158 ± 5.53 11.20 ± 0.39 96.9 ± 2.39 218 ± 7.63 2.87 ± 0.100 
F5 166 ± 5.81 10.73 ± 0.37 98.8 ± 2.45 220 ± 7.70 2.86 ± 0.105 
F6 154 ± 5.39 10.97 ± 0.38 95.8 ± 2.35 200 ± 7.00 2.96 ± 0.103 
F7 165 ± 5.77 11.21 ± 0.39 97.8 ± 2.42 208 ± 7.28 3.15 ± 0.110 
F8 160 ± 5.61 10.87 ± 0.38 98.6 ± 2.45 196 ± 6.86 3.18 ± 0.111 
F9 151 ± 5.28 11.52 ± 0.40 99.9 ± 2.49 212 ± 7.42 3.00 ± 0.106 
mean ± SD (n=3) 
 
Drug Content 
Patches of specified area (1 cm2) were dissolved in 5 
mL of dichloromethane and the volume was made up 
to 10 mL with phosphate buffer pH 7.4; 
dichloromethane was evaporated using a rotary 
vacuum evaporator at 45 °C. A blank was prepared 
using a drug-free patch treated similarly. The 
 43
Patel et al. International Journal of Drug Delivery 1(2009) 41-51 
 
solutions were filtered through a 0.45 μm membrane, 
diluted suitably and absorbance was read at 274 nm in 
a double beam UV-Vis spectrophotometer. 
 
Flatness 
Three longitudinal strips were cut out from each film: 
1 from the center, 1 from the left side, and 1 from the 
right side. The length of each strip was measured and 
the variation in length because of non-uniformity in 
flatness was measured by determining percent 
constriction, with 0% constriction equivalent to 100% 
flatness [18]. 
 
Folding Endurance 
This was determined by repeatedly folding one film at 
the same place till it broke. The number of times the 
film could be folded at the same place without 
breaking/cracking gave the value of folding 
endurance [21]. 
 
Tensile strength 
In order to determine the elongation as a tensile 
strength, the polymeric patch was pulled by means of 
a pulley system; weights were gradually added to the 
pan to increase the pulling force till the patch was 
broken. The elongation i.e. the distance traveled by 
the pointer before break of the patch was noted with 
the help of magnifying glass on the graph paper, the 
tensile strength was calculated as kg cm-2. 
 
Percentage of Moisture Content 
The films were weighed individually and kept in a 
desiccators containing activated silica at room 
temperature for 24 hours. Individual films were 
weighed repeatedly until they showed a constant 
weight. The percentage of moisture content was 
calculated as the difference between initial and final 
weight with respect to final weight [22]. 
 
Water vapour transmission rate (WVTR) 
WVTR is defined as the quantity of moisture 
transmitted through unit area of film in unit time [23]. 
Glass cells were filled with 2 g of anhydrous calcium 
chloride and a film of specified area was affixed onto 
the cell rim. The assembly was accurately weighed 
and placed in a humidity chamber (80 ± 5% RH) at 27 
± 2 °C for 24 hours. 
 
In-vitro skin permeation studies 
In-vitro skin permeation studies were 
performed by using a Franz diffusion cell with a 
receptor compartment capacity of 22.5 mL. The 
excised rat abdominal skin (Wistar albino) was 
mounted between the donor and receptor 
compartment of the diffusion cell. The formulated 
patches were placed over the skin and covered with 
paraffin film. The receptor compartment of the 
diffusion cell was filled with phosphate buffer pH 7.4. 
The whole assembly was fixed on a magnetic stirrer, 
and the solution in the receptor compartment was 
constantly and continuously stirred using magnetic 
beads at 50 rpm; the temperature was maintained at 
32 ± 0.5 °C. The samples were withdrawn at different 
time intervals and analyzed for drug content 
spectrophotometrically. The receptor phase was 
replenished with an equal volume of phosphate buffer 
pH 7.4 at each sample withdrawal. The cumulative 
percentages of drug permeated per square centimeter 
of patches were plotted against time. 
 
Full factorial design 
A 32 randomized full factorial design was used in the 
present study. In this design two factors were 
evaluated, each at 3 levels, and experimental trials 
were performed at all 9 possible combination. The 
amount of Oleic acid (X1) and the amount of 
Isopropyl myristate (X2) were selected as independent 
variables. The drug release at 8 hrs was selected as 
dependent variable. The design lay out is depicted in 
Table 4. 
 
Permeation Data Analysis 
The flux (µg cm-2 hr-1) of ACF was calculated from 
the slope of the plot of the cumulative amount of ACF 
permeated per cm2 of skin at steady state against the 
time using linear regression analysis [24,25]. 
The steady state permeability coefficient (Kp) of the 
drug through rat epidermis was calculated by using 
the following equation [26]: 
          C
JKp =                              (1) 
where J is the flux and C is the concentration 
of ACF in the patch. The penetration enhancing effect 
of penetration enhancer was calculated in terms of 
enhancement ratio (ER), and was calculated by using 
the following equation [27 ]: 
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enhancernpenetratiowithoughtKp
enhancernpenetratiowithKpER =     (2) 
 
 
Table 4: 32 full factorial design layouts for ACF transdermal 
patches 
 
Variables 
levels in 
coded 
form 
Batch 
No 
X1 X2 
Q8hr 
release  
(%) 
Flux (J) 
(µg cm-
2 hr-1)  
Permeability 
co efficient 
(KP)  
(cm hr-1) 
Enhancement 
ratio 
(ER) 
F1 -1 -1 70.58 216.54 5.310 1.000 
F2 -1 0 84.36 249.97 5.839 1.099 
F3 -1 +1 90.31 263.26 6.077 1.144 
F4 0 -1 81.13 242.56 6.024 1.134 
F5 0 0 91.71 267.23 6.318 1.189 
F6 0 +1 93.75 271.66 6.923 1.303 
F7 +1 -1 88.14 256.57 6.103 1.149 
F8 +1 0 96.90 274.75 6.739 1.268 
F9 +1 +1 99.64 279.89 7.274 1.369 
Translation of coded levels in actual units 
Variables level Low (-1) Medium (0) High (+1) 
Amount of Oleic acid (% 
W/W of drug) X1 
0 5 15 
Amount of Isopropyl 
myristate (% W/W of drug) X2 
0 5 10 
 
 
Kinetic modeling of drug release  
To analyze the mechanism of drug release from the 
patches, the release data were fitted to the following 
equations: 
Zero-order equation: 
                                                                            
tkQ 0=                                            (3) 
Where Q is the amount of drug released at time t, and 
k0   is the release rate. 
 
Table 5: Summary of Results of Regression Analysis for Q8hr 
Response bo b1 b2 b11 b22 b12 
FM 91.35 6.571 7.308 -0.541 -3.732 -2.057 
RM 90.99 6.571 7.308 - -3.732 -2.057 
*FM indicates full model and RM indicates reduced model 
 
First-order equation: 
                                   
tkQ 1100ln)100(ln −=−                  (4) 
Where Q is the percent of drug release at time t, and 
k1 is the release rate constant. 
 
Higuchi’s equation: 
tkQ 2=                                   (5) 
Where Q is the percent of drug release at time t, and 
k2   is the diffusion rate constant. 
 
 
Table 6: Calculation for testing the model in portions 
 
 
 
 
 
 
 
*DF indicates: degrees of freedom; SS, sum of squares; F, Fischer’s 
ratio; R2, regression coefficient; FM, full model; and RM, reduced 
model. 
 
Stability study of optimized formulation 
 
Stability study was carried out for optimized patch 
formulation at 40oC temperature in a humidity 
chamber having 75 % RH for 3 months. After 3 
months samples were withdrawn and evaluated for 
physicochemical properties and in-vitro diffusion 
study. 
 
Results and Discussion 
 
Investigation of Physicochemical Compatibility of 
Drug and Polymer 
 
Differential scanning calorimetry enables the 
quantitative detection of all processes in which energy 
is required or produced (i.e. endothermic or 
Regression DF SS MS F R2
FM 5 624.96 124.99 105.54 0.9971 
RM 4 624.37 156.09 150.83 0.9967 
Error      
FM 3 3.55 1.184 - - 
RM 4 4.14 1.035 - - 
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exothermic phase transformations). The thermograms 
of ACF (A), HPC (B), physical mixture of ACF with 
excipient of HPC patch formulation (C), EC (D) and 
physical mixture of ACF with excipient of EC patch 
formulation (E) are presented in Figure 1. The ACF 
showed a melting peak at 158.22 °C. Peak of ACF at 
158.22 °C was present at the same position i.e. near to 
160 oC in the physical mixture of drug with both HPC 
and EC patch formulation excipients. This confirmed 
the physicochemical stability of drug with the 
formulation excipient used in the study. 
 
 
 
 
Figure 1: DSC study of ACF (A), HPC (B), physical mixture of 
HPC formulation excipient with ACF (C), EC (D), physical mixture 
of EC formulation excipients with ACF (E) 
 
 
 
Drug - excipient interactions play a vital role with 
respect to release of drug from the formulation 
amongst others. FTIR techniques have been used here 
to study the physical and chemical interaction 
between drug and excipients used. Infrared (IR) 
spectra of ACF (A), physical mixture of ACF with 
excipients of HPC patch formulation (B) and physical 
mixture of ACF with excipients of EC patch 
formulation (C) are shown in Figure 2. Infrared 
absorption spectroscopy (IR) of ACF showed sharp 
band at 3319, 3278 and 1770 cm-1 due to stretching 
vibration bands of OH, N-H and C=O, respectively. 
From the figure it was observed that there were no 
changes in these main peaks in IR spectra of mixture 
of drug and polymers, which show there were no 
physical interactions because of some bond formation 
between drug and polymers. 
 
 
 
 
Figure 2: FTIR spectra of ACF (A), physical mixture of HPC with 
ACF (B), physical mixture of EC with ACF (C) 
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Table 7: Kinetic modeling of drug release 
 
Formulation 
code Zero order First order Higuchi 
F1 0.9975 0.9966 0.9365 
F2 0.9928 0.9925 0.9660 
F3 0.9884 0.9901 0.9741 
F4 0.9955 0.9951 0.9604 
F5 0.9834 0.9838 0.9802 
F6 0.9781 0.9809 0.9847 
F7 0.9902 0.9885 0.9692 
F8 0.9692 0.9669 0.9901 
F9 0.9595 0.9576 0.9935 
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Figure 3: Release profile of ACF from patches containing different 
concentration of HPC and EC, mean ± SD (n = 3) 
 
Physicochemical characterization of films 
The results of the physicochemical 
characterization of the patches are shown in Table 2. 
The thickness ranged between 120 ± 3.6 and 215 ± 
6.45 μm, which indicate that they are uniform in 
thickness. The weights ranged between 10.11 ± 0.30 
mg and 15.13 ± 0.45 mg, which indicates that 
different batches patch weights, were relatively 
similar. Good uniformity of drug content among the 
batches was observed with all formulations and 
ranged from 97.9 ± 2.93 % to 99.2 ± 2.97 %. The 
results indicate that the process employed to prepare 
patches in this study was capable of producing 
patches with uniform drug content and minimal patch 
variability. The flatness study showed that all the 
formulations had the same strip length before and 
after their cuts, indicating 100% flatness. Thus, no 
amount of constriction was observed; all patches had 
a smooth, flat surface; and that smooth surface could 
be maintained when the patch was applied to the skin. 
Folding endurance test results indicated that the 
patches would not break and would maintain their 
integrity with general skin folding when applied. 
Moisture content and moisture uptake studies 
indicated that the increase in the concentration of 
hydrophilic polymer was directly proportional to the 
increase in moisture content and moisture uptake of 
the patches. The moisture content of the prepared 
formulations was low, which could help the 
formulations remain stable and reduce brittleness 
during long term storage. The moisture uptake of the 
formulations was also low, which could protect the 
formulations from microbial contamination and 
reduce bulkiness [28]. 
 
In-vitro skin permeation 
The in-vitro release profile is an important 
tool that predicts in advance how a drug will behave 
in vivo [29]. The results of in-vitro skin permeation 
studies of ACF from transdermal patches are shown 
in Figures 3. In the present study hydrophilic (HPC) 
and hydrophobic (EC) polymers are used to prepared 
patches. Formulation A1 exhibited greatest 84.8 ± 
3.39 % of drug release value, while formulation A6 
exhibit lowest 44.73 ± 1.789 % of drug release value.  
The cumulative amount of drug released from 
formulations containing hydrophilic polymer release 
drug at faster rate than hydrophobic polymer. The 
cumulative amount of drug released from 
formulations A1, A2 and A3 is much higher than 
formulation A4, A5 and A6. In addition to nature of 
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polymer concentration of polymer also affect the drug 
release. As the concentration of polymer increased  
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Figure 4: Release profile of ACF from formulation F1 - F9 
 
 
drug release decreased. The drug release from the 
patch is ordered as A1 > A2 > A3 > A4 > A5 > A6. 
Unlike the formulations A2, A3, A4, A5 and A6, the 
formulations A1 achieved a high cumulative amount 
of drug permeation at the end of 10 hours. Based on 
physiochemical and in-vitro release experiments, A1 
was chosen for further studies. 
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Full factorial design 
 
Physicochemical properties of factorial design 
batches 
The results of the physicochemical characterization of 
the patches are shown in Table 3. 
 
In-vitro drug release study of factorial design 
batches 
The cumulative percentage of drug permeated 
through the rat epidermis from the patch containing 
different concentration of penetration enhancer is 
shown in Figure 4. Table 5 shows the results of 
analysis of variance (ANOVA), which was performed 
to identify independent factors. The high value of 
correlation coefficient for Q8hr indicates a good fit. 
The equation can be used to obtained estimates of the 
response as a small error of variance was noticed in 
the replicates. The significant level of coefficients b11 
was found to be greater than P = 0.05. Hence it was 
omitted from the full model to generate the reduced 
model. The results of statistical analysis are shown in 
Table 5. The coefficients b1, b2, b22 and b12 were 
found to be significant at P < 0.05. Hence they were 
retained in the reduced model. An increase in 
concentration of Oleic acid leads to an increase in 
Q8hr because the coefficient b1 bears positive sign. 
Increasing the concentration of oleic acid from 5 to 10 
%, Q8hr value increased from 81.13 % to 88.14 %. An 
increase in concentration of Isopropyl Myristate leads 
to increase in Q8hr because the coefficient b2 bears 
positive sign. As increasing concentration of 
Isopropyl myristate from 5 to 10 % the Q8hr value 
increased from 84.36 % to 90.31 %.  
Here the coefficient of interaction terms showed 
negative value. The interaction term indicate that Q8hr 
was not significantly affected by interaction of two 
penetration enhancer. This indicates that by changing 
two factors at a time there no effect on Q8hr. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Drug release profile of ACF before and after stability 
study for formulation F9 
 
 
The maximum amount (Q8hr) of ACF that permeated 
during the 8 hr of the study was 99.64 % from 
formulation F9. The flux was calculated by dividing 
the cumulative amount of drug permeated per cm2 of 
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the skin with time. Thus the corresponding flux of 
ACF was 216.54 µg cm-2 hr-1 from formulation F1 
(transdermal patch without penetration enhancer). A 
marked effect of penetration enhancer on ACF 
permeation was observed when they were 
incorporated in patch in varying concentration. The 
cumulative percentage of ACF that permeated over 8 
hr was found to increase ranging from 81.13 to 99.64 
% for HPC patches. The corresponding flux values 
were ranging from 242.56 to 256.57 µg cm-2 hr-1. 
Formulation F9 shows highest flux among all the 
formulation. Formulation F9 shows 1.369 fold 
enhancements in drug permeation. This result indicate 
that the formulation containing 15 % of oleic acid 
with 10 % Isopropyl myristate give better penetration 
of ACF through rat skin.  
 
Kinetic modeling of drug release 
The cumulative amount of drug permeated per square 
centimeter of patches through rat skin was plotted 
against time was fitted to zero, first and higuchi 
kinetic model. As indicated in Table 7, the release 
profile of ACF followed mixed zero-order and first-
order kinetics in different formulation. However, the 
release profile of the optimized formulation F9 (r2 = 
0.9935 for Higuchi) indicated that the permeation of 
the drug from the patches was governed by a 
diffusion mechanism.  
 
Stability study 
In order to determine the change in physicochemical 
parameter and in-vitro release profile on storage, 
stability study was carried out. The physicochemical 
parameter of the optimized formulation was not 
significantly changed on storage. The in-vitro release 
profile before and after storage is shown in Figure 5. 
The result indicates that the formulation was stable on 
the required storage condition. 
 
Conclusion 
 
The method of preparation of transdermal patches of 
Aceclofenac presented in this research work is 
simple. All formulation also showed good 
physicochemical properties like thickness, weight 
variation, drug content, flatness, folding endurance, 
moisture content and moisture uptake. The in-vitro 
release data showed that drug release from the patch 
formulation have been affected by types of polymer 
and concentration of polymer. Effect of penetration 
enhancer like oleic acid and isopropyl myristate have 
been checked on in-vitro permeation of drug. These 
studies indicated that as the concentration of 
penetration enhancer increased drug permeation was 
increased. The finding of this result revealed that the 
problems of Aceclofenac on oral administration like 
dissolution rate limited absorption and gastric side 
effects can be overcome by applying Aceclofenac 
topically in the form of transdermal patch. 
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